Traduction de «health outcomes associated with antagonists » (Néerlandais → Français) :

The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).JAMA 2002; 288: 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstline antihypertensive therapies : a meta-analysis of randomised controlled trials.
The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002 ; 288 : 2981-2997 (5) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other firstlineantihypertensive therapies : a meta-analysis of randomised controlled trials.

JAMA 2002 ; 288 :2981-2997 (6) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other first-line antihypertensive therapies : a meta-analysis of randomised controlled trials.
JAMA 2002 ; 288 : 2981-2997 (6) PAHOR M, PSATY B, ALERMAN M et al. Health outcomes associated with antagonists compared with other first-line antihypertensive therapies : a meta-analysis of randomised controlled trials.

[2] Kramer, M.S et al. Infant growth and health outcomes associated with 3 compared with 6 mo of exclusive breastfeeding.
[2] Kramer, M.S et al. Infant growth and health outcomes associated with 3 compared with 6 mo of exclusive breastfeeding.

al. Health outcomes associated with various antihypertensive therapies used as first-line agnets: a network meta-analysis.
et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.

Journal of Hypertension 2003; 21 : 1011-1053 (10) PSATY B, LUMLEY T, FURBERG C et al. Health outcomes associated with various antihypertensive therapies used as first-line agents.
Journal of Hypertension 2003; 21 : 1011-1053 (10) PSATY B, LUMLEY T, FURBERG C et al. Health outcomes associated with various antihypertensive therapies used as first-line agents.

WAMPOLD B.E., « The Great Psychotherapy Debate : Models, Methods and Findings », London, 2001, Erlbaum. WEBER J., BACHRACH H., SOLOMON M., « Factors associated with the outcome of psychoanalysis : Report of th Colombia Psychoanalytic Center Research Project (II) », International Review of Psychoanalysis, 1985a, 12 : 127-141.
SASHIN J.I. , ELDRED S.H. & VAN AMEROGEN S.T., « A search of predictive factors in institute supervised cases : a retrospective study of 183 cases from 1959- 1966 at the Boston Psychoanalytic Society and Institute », International Journal of Psychoanalysis, 1975, 56 : 343-359.

WEBER J., BACHRACH H., SOLOMON M., « Factors associated with the outcome of psychoanalysis : Report of th Colombia Psychoanalytic Center Research Project (III) », International Review of Psychoanalysis, 1985b, 12 : 251-262.
SAUVAGNAT F., « La place de la procédure de la passe dans les recherches sur le processus psychanalytique », Mental (Revue internationale de santé mentale et psychanalyse appliquée), 1997, 3 : 27-59. SAUVAGNAT F., « On the lacanian treatment of psychotics : historical background and future prospects », Psychoanalytic Review, 2003, 90, 3 : 303-328.

The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.
The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

Gezondheidsrisico’s van ultrasone dierenverdrijvers Assessment of the risks to human health associated with ultrasonic animal repellers
Risques pour la santé des répulsifs à ultrasons pour animaux Assessment of the risks to human health associated with ultrasonic animal repellers